Clinical Trial Accrual
Overcoming Barriers to Advancing Cancer Treatment
Across ClinicalPath (formerly Via Oncology) customer institutions with a strong focus on research, we see an overall accrual rate of 10% (2x the national average) and when a trial is available, patient accrual is 20% (4x the national average).

Challenges

- Clinical trials are critical to the development of new cancer therapies, but so much stands in the way.
- While clinical trial treatment is considered on-guideline and may result in a lower financial burden to the patient, the national average of cancer patients accrued to clinical trials is only 2-4%.
  This results in early study closure and delays in creating life-saving drugs.
- Studies have identified barriers at multiple levels:
  - At the institution level, defining the optimal set of clinical trials for your patient population.
  - At the provider level, awareness of trials and accruing patients appropriately.
  - At the patient level, access to trials, based on their treatment site. Trials at community sites may be more restricted than for patients treated at academic centers.

Opportunity

Institutions with a robust clinical trial program can benefit from:

- Reimbursement for participating sites, with industry-sponsored trials providing up to $15,000 per patient enrolled.
- A competitive advantage, attracting patients interested in accessing precision medicine options that may not be available at their current institution.
- Accreditation as an NCI Comprehensive Cancer Center, including the opportunity to apply for up to $1.5m in research funding.

In pediatric populations where clinical trial accrual rates are greater than 50%, mortality has been decreasing since 1970 by 2.6% per year.
How Elsevier’s ClinicalPath Can Help Your Institution

For your providers:

• View institution-specific clinical trials, ahead of standard of care recommendations, making it easier to identify patients for screening.

• View patient-specific clinical trials, because trials are placed at specific branches of the pathway based on trial inclusion/exclusion criteria.

• Links to trial documents from within the workflow for easy access to additional information.

For your patients:

• Visibility into trials across your institution, including at community and academic sites.

• Increased likelihood of accrual (over 70% of cancer patients indicate they would be interested in participating in a trial). iii

• Access new cancer therapies closer to home, increasing compliance.

For your institution:

• Get detailed analytics on patient accrual rates, trial availability and patient presentation characteristics, at the site and provider level — enabling your leadership team to make informed decisions on the optimal trials for your organization.

• Support workflow coordination between physicians and research teams through secure messaging. ClinicalPath also interfaces with trial management systems for automated updating of trial status.

A multi-site oncology practice leveraged the ClinicalPath clinical trial functionality to raise trial participation for lung cancer patients to 25%, more than 5x the national average.
Resources

i Clinical Trial Accrual: Obstacles and Opportunities, Frontiers in Oncology, April 25, 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843106/


To learn more, visit Elsevier.com/clinicalpath